A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
17/02/2022at 09:01

Genmab raises 2022 sales outlook to top USD 1.6bn

Biotech firm Genmab is once again counting on sales advancements, projecting a revenue of DKK 10.8–12bn (USD 1.6–1.8bn) in the current financial year.
Photo: Tuala Hjarnø / Genmab / PR
by ANDREAS LØNSTRUP, translated by daniel pedersen

Genmab ended 2021 with a revenue of DKK 8.5bn (USD 1.3bn), compared to DKK 10.1bn (USD 1.5bn) in 2020, and an operating profit (EBIT) of DKK 3bn (USD 461m) against DKK 6.3bn (USD 964m) the preceding year, when an extraordinary one-off payment of DKK 4.4bn (USD 672m) from partner Abbvie lifted profits.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Joost Melis / Genmab / PR

    Analyst ahead of Genmab report: Focus will be on Darzalex prognosis

    For subscribers

  • Jan van de Winkel, CEO at Genmab | Photo: Stine Bidstrup/Ritzau Scanpix

    Abbvie to submit first Genmab collaboration candidate in 2022

    For subscribers

  • Photo: CHARLES PLATIAU/Reuters / X00217

    Novartis increases sales of Genmab-developed sclerosis drug

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
  • Novo Nordisk doubles obesity sales in 2022
  • New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Photo: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Further reading

Foto: Lukas Barth/Reuters/Ritzau Scanpix
Pharma & biotech

Bank raises expectations for Bavarian Nordic's 2023 outlook

Danske Bank believes Bavarian Nordic is well on the way to secure another record-breaking year after having seen preliminary figures for the drugmaker’s 2022 performance on Monday.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

JPMorgan: Novo Nordisk to accelerate growth this year

Obesity drug Wegovy has made the US-based investment bank turn up its expectations for the Danish drugmaker.

For subscribers

Foto: Coloplast / Pr
Medtech

Analyst: Better conditions in China to ease Coloplast's cost pressure

Coloplast has been intensely focused on costs as of late, but Danske Bank now thinks a Chinese relaxation of pandemic restrictions will dispel the worst concerns. 

For subscribers

Latest news

  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Application Manager

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Lead Data Architect

  • Experienced Patent Counsel

See all jobs

Jobs

  • Application Manager

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Commercial Director

  • Lead Data Architect

  • Experienced Patent Counsel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge